Episurf Medical

Episurf Medical AB ("Episurf") (Nasdaq: EPIS B) today announces that the company is changing liquidity provider from Pareto Securities AB to Mangold Fondkommission AB ("Mangold") as of August 29, 2025.

Episurf has entered into an agreement with Mangold regarding the role as liquidity provider. Mangold will commence the role on August 29, 2025.

The liquidity provider commitment is provided in accordance with Nasdaq Stockholm AB's rules for liquidity providers, which means that the liquidity provider quotes buy and sell volumes with the aim of creating a more accurate representation of the stock price. This gives a more reliable valuation of the company and enhances the liquidity of the stock.

For more information, please contact:
Pål Ryfors, CEO and interim CFO, Episurf Medical
Tel:+46 709 62 36 69
Email: pal.ryfors@episurf.com

The information was submitted for publication, through the agency of the contact person set out above, at 08:00 CEST on August 29, 2025.

About Episurf Medical

Episurf Medical is endeavoring to bring people with painful joint injuries a more active, healthier life through the availability of minimally invasive and individualised treatment alternatives. Episurf Medical's Episealer^® individualised implants and Epiguide^® surgical drill guides are developed for treating localised cartilage injury in joints. Episurf Medical's μiFidelity^® system enables implants to be cost-efficiently tailored to each individual's unique injury for the optimal fit and minimal intervention. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, go to the company's website: www.episurf.com.